Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cirrhosis

Cirrhosis

Subtypes of Cirrhosis

Primary biliary cholangitis 8 Liver Fibrosis 7 Decompensated liver cirrhosis 6 End-stage liver disease 4 Fibrosis 4 Compensated cirrhosis 3 Keloid 3 Acute decompensation of cirrhosis 1 Compensated MASH cirrhosis 1 Decompensated liver failure 1

52 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cirrhosis

82 trials tracked for Cirrhosis: 27 in phase 3 or 4 and 2 with published results. The most-cited published study has 45 citations.

82Trials tracked
27Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 12 Phase 3 15 Phase 2 22 Phase 1 3 Other / NA 30
  1. Phase 4 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Completed · 45 cited
  2. Phase 3 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Completed · 21 cited
  3. Phase 4 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed
  4. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  5. Phase 4 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant Completed
  6. Phase 4 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis Completed
Show 44 more trials
  1. Phase 4 Ramelteon for Treatment of Insomnia in Cirrhosis Completed
  2. Phase 4 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed
  3. Phase 4 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Completed
  4. Phase 4 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed
  5. Phase 4 Tolvaptan for Ascites in Cirrhotic Patients Completed
  6. Phase 4 Steroid Free Immunosuppression in Liver Transplantation Completed
  7. Phase 4 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed
  8. Phase 3 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  9. Phase 3 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study Completed
  10. Phase 3 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? Completed
  11. Phase 3 A Trial to Improve Quality of Life in People With Cirrhosis Completed
  12. Phase 3 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Completed
  13. Phase 3 Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) Completed
  14. Phase 3 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis Completed
  15. Phase 3 Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) Completed
  16. Phase 3 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema Completed
  17. Phase 3 PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) Completed
  18. Phase 3 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema Completed
  19. Phase 3 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg Completed
  20. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  21. Phase 3 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) Completed
  22. Phase 2 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Completed
  23. Phase 2 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients Completed
  24. Phase 2 FMT in Cirrhosis and Hepatic Encephalopathy Completed
  25. Phase 2 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation Completed
  26. Phase 2 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Completed
  27. Phase 2 A Study of IDN-6556 in Subjects With Liver Cirrhosis Completed
  28. Phase 2 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Completed
  29. Phase 2 VE303 for Treatment of Hepatic Encephalopathy (HE) Completed
  30. Phase 2 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Completed
  31. Phase 2 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Completed
  32. Phase 2 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Completed
  33. Phase 2 A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients Completed
  34. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  35. Phase 2 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C Completed
  36. Phase 2 Human Fetal Liver Cell Transplantation in Chronic Liver Failure Completed
  37. Phase 2 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study Completed
  38. Phase 2 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Completed
  39. Phase 2 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema Completed
  40. Phase 2 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Completed
  41. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  42. Phase 2 MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Completed
  43. Phase 2 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer Completed
  44. Phase 1 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis Completed

Showing the 50 most-cited and recently-updated of 82 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Oncology Sys. Review
Narrative review explores macrophage reprogramming for liver fibrosis and MASH Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Frontiers May 17, 2026
Systematic review shows high fatigue and pruritus prevalence in primary biliary cholangitis patients
Gastroenterology Meta-analysis
Systematic review shows high fatigue and pruritus prevalence in primary biliary cholangitis patients Half of liver disease patients battle severe fatigue and itching
This systematic review and meta-analysis evaluated symptom burden in 13178 patients with primary biliary cholangitis. Fatigue affected 51% o…
Over half of patients with primary biliary cholangitis face severe fatigue and itching, yet most never get proper treatment for these sympto…
May 13, 2026
Narrative review on sepsis in end-stage liver disease and acute-on-chronic liver failure
Drug Pipeline Sys. Review
Narrative review on sepsis in end-stage liver disease and acute-on-chronic liver failure Patients with severe liver disease and sepsis face high risks and need careful care plans
This narrative review synthesizes evidence on sepsis in patients with end-stage liver disease and acute-on-chronic liver failure. It describ…
People with advanced liver sickness and sepsis often have weak immune systems and get hard-to-treat infections. Doctors say new treatments l…
Frontiers May 7, 2026
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis
Gastroenterology RCT
Zibotentan plus dapagliflozin shows no HVPG reduction in compensated cirrhosis Early trial shows zibotentan plus dapagliflozin trended toward lowering blood pressure in cirrhosis patients
This Phase II randomized placebo-controlled exploratory study in 28 patients with compensated cirrhosis found that zibotentan 2.5 mg plus da…
An early study found that a combination drug lowered blood pressure in patients with compensated cirrhosis, though it did not conclusively i…
May 1, 2026
Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care
Gastroenterology RCT
Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care App helps cirrhosis patients avoid hospital readmission
This randomized clinical trial enrolled 464 subjects (232 dyads) with cirrhosis in a multicenter setting.
A smartphone app cut avoidable hospital readmissions in half for cirrhosis patients, a new trial shows.
May 1, 2026
Five ACLF diagnostic models and prognostic scores identified markedly different proportions of patients at risk of 28-day mortality in a cohort study
Gastroenterology Cohort
Five ACLF diagnostic models and prognostic scores identified markedly different proportions of patients at risk of 28-day mortality in a cohort study Two new models find the sickest liver patients faster than old tools
This cohort study evaluated five acute-on-chronic liver failure (ACLF) diagnostic models and prognostic scores in 3,370 patients from the CO…
Two new scoring systems find the most dangerous liver failure patients better than older tools, potentially saving lives by catching risk ea…
medRxiv May 1, 2026
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
Gastroenterology Meta-analysis
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
May 1, 2026
Systematic review finds weak link between atypical antipsychotics and MASLD in youth
Gastroenterology Meta-analysis
Systematic review finds weak link between atypical antipsychotics and MASLD in youth Atypical antipsychotics show a small link to liver disease in young patients
This systematic review and meta-analysis of 3 studies examined the association between atypical antipsychotics and metabolic dysfunction-ass…
A review of three studies found a small link between atypical antipsychotics and liver disease in children, but the evidence is limited.
May 1, 2026
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency
Gastroenterology Meta-analysis
Systematic review shows high rates of fibrosis and cirrhosis in children with Pi*ZZ alpha-1 antitrypsin deficiency 1 in 4 children with A1AT deficiency develop cirrhosis
This systematic review and meta-analysis examined children with confirmed Pi*ZZ alpha-1 antitrypsin deficiency to assess liver outcomes.
New analysis finds 41% of children with A1AT deficiency have liver fibrosis and 17% have cirrhosis.
May 1, 2026
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients
Gastroenterology Meta-analysis
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients New drugs ease itch for patients whose current treatment fails
This systematic review and meta-analysis of 660 patients with primary biliary cholangitis and inadequate response to UDCA found that PPAR ag…
A review of six hundred sixty patients found new medicines significantly reduced itch scores in people with primary biliary cholangitis who …
May 1, 2026
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Oncology Meta-analysis
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Apr 28, 2026
L-taurine shows no overall fatigue benefit in decompensated cirrhosis but may help non-anemic patients
Gastroenterology RCT
L-taurine shows no overall fatigue benefit in decompensated cirrhosis but may help non-anemic patients Taurine for cirrhosis fatigue fails overall but helps one group
This randomized controlled trial in 220 adults with decompensated cirrhosis found no significant difference in fatigue scores with L-taurine…
Taurine did not reduce fatigue in most cirrhosis patients, but those without anemia saw meaningful improvement, suggesting a targeted approa…
Apr 28, 2026

Questions about Cirrhosis

How common is depression among patients with liver cirrhosis?

Depression is very common in liver cirrhosis, affecting about 37% of patients globally, yet it often goes undiagnosed.

Full answer →
Can the Patient Buddy App help reduce hospital readmissions for my cirrhosis?

Yes, the Patient Buddy App reduced avoidable hospital readmissions in cirrhosis patients by about half in a clinical trial, but discuss with your doctor if it's right for you.

Full answer →